As Chief Commercial Officer of Hemostemix, I am leading commercialization and patient services for our pioneering autologous stem cell therapy, ACP-01, to restore health for patients with cardiovascular, dermatological, and neurological diseases. We are disrupting the standard of care for ischemic disease, from heart failure to wound care to vascular dementia, by providing a science-backed, personalized cellular therapy for those with limited or no other options. My mission is to ensure these life-changing treatments reach the individuals who need them most.